Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS-20094. The agreement will involve the clinical development and ...

Strategic in-licensing agreement with Hansoh Pharmaceuticals provides exclusive rights to develop and commercialize HS-20094, enhancing Regeneron's pipeline in obesity and metabolic programs.

Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss Sep. 25, 2023 8:34 AM ET Regeneron Pharmaceuticals, Inc. (REGN) ...

Hansoh has already studied the drug in more than 1,000 patients, according to Regeneron, which claimed that HS-20094 has a “potentially similar profile” to Lilly’s approved GLP-1/GIP agonist.